Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)
Sutro Biopharma (STRO) posted Net Cash Flow of -$7.8 million for Q4 2025, down 509.94% sequentially from $1.9 million in Q3 2025, and down 149.58% YoY from $15.7 million in Q4 2024.
Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025) Analysis & Trends
Sutro Biopharma has reported Net Cash Flow for 9 years, with the latest figure at -$7.8 million in Q4 2025.
- Quarterly Net Cash Flow fell 149.58% year-over-year to -$7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.2 million (down 209.21% YoY) and the FY2025 annual result came in at -$132.2 million, down 209.21% from the prior year.
- Net Cash Flow fell to -$7.8 million in Q4 2025 per STRO's latest filing, from $1.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $172.6 million in Q2 2023 and troughed at -$153.3 million in Q3 2023.
- A 5-year average of -$7.4 million and a median of -$903000.0 in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2022: Net Cash Flow sank 21127.27% in 2021, then surged 8648.08% in 2022.
- Over 5 years, Net Cash Flow stood at -$293000.0 in 2021, then slumped by 16802.73% to -$49.5 million in 2022, then soared by 74.63% to -$12.6 million in 2023, then surged by 225.15% to $15.7 million in 2024, then slumped by 149.58% to -$7.8 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$7.8 million, $1.9 million, and -$42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.80 Mn |
| Dec 31, 2025 | -7.80 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | -42.20 Mn |
| Jun 30, 2025 | -42.20 Mn |
| Mar 31, 2025 | -84.08 Mn |
| Mar 31, 2025 | -84.08 Mn |
| Dec 31, 2024 | 15.73 Mn |
| Dec 31, 2024 | 15.73 Mn |
| Sep 30, 2024 | 83.79 Mn |
| Sep 30, 2024 | 83.79 Mn |
| Jun 30, 2024 | 25.57 Mn |
| Jun 30, 2024 | 25.57 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Dec 31, 2023 | -12.57 Mn |
| Dec 31, 2023 | -12.57 Mn |
| Sep 30, 2023 | -153.26 Mn |
| Sep 30, 2023 | -153.26 Mn |